Kestra Medical Technologies (NASDAQ:KMTS) Releases Quarterly Earnings Results, Misses Expectations By $0.61 EPS

Kestra Medical Technologies (NASDAQ:KMTS) issued its earnings results on Monday. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61), RTT News reports.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS traded down $0.45 during trading hours on Monday, reaching $23.83. 131,018 shares of the stock traded hands, compared to its average volume of 272,564. Kestra Medical Technologies has a 52-week low of $20.00 and a 52-week high of $26.06.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on KMTS shares. Bank of America started coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued a “buy” rating and a $30.00 price target on the stock. Wells Fargo & Company began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an “overweight” rating and a $28.00 target price on the stock. Piper Sandler assumed coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an “overweight” rating and a $27.00 price objective on the stock. The Goldman Sachs Group started coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued a “neutral” rating and a $24.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set a “buy” rating and a $28.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.